XML 33 R22.htm IDEA: XBRL DOCUMENT
v3.7.0.1

Intangible Assets | 9 Months Ended
--- | ---
Jul. 01, 2017
Goodwill and Intangible Assets Disclosure [Abstract] |
Intangible Assets | Intangible Assets Intangible assets consisted of the following:
Description | As of July 1, 2017 |  | As of September 24, 2016
Gross Carrying Value |  | Accumulated Amortization |  | Gross Carrying Value |  | Accumulated Amortization
Developed technology | $ | 4,467.5 |  |  | $ | 2,107.5 |  |  | $ | 3,983.7 |  |  | $ | 1,991.6 |
In-process research and development | 107.0 |  |  | — |  |  | 3.7 |  |  | — |
Customer relationships | 552.2 |  |  | 384.2 |  |  | 1,098.9 |  |  | 546.2 |
Trade names | 310.2 |  |  | 151.6 |  |  | 236.2 |  |  | 141.6 |
Non-competition agreements | 1.5 |  |  | 0.1 |  |  | — |  |  | — |
Distribution agreement | 42.0 |  |  | 1.5 |  |  | — |  |  | — |
Business licenses | 2.4 |  |  | 2.1 |  |  | 2.4 |  |  | 2.1 |
| $ | 5,482.8 |  |  | $ | 2,647.0 |  |  | $ | 5,324.9 |  |  | $ | 2,681.5 |
During the second quarter, the Company divested its blood screening business and as such $154.0 million of net book value of developed technology and $387.7 million of net book value of customer contract assets were disposed of. In addition, in the second quarter of fiscal 2017, the Company acquired Cynosure and recorded an aggregate of $994.0 million of intangible assets (see Note 3). In the third quarter of fiscal 2017, the Company acquired Medicor and recorded $5.4 million of intangible assets. In addition, during the third quarter of fiscal 2017, the Company obtained CE approval for its last in-process research and development project acquired in the Gen-Probe Incorporated acquisition and transferred $3.7 million to developed technology. In the third quarter of fiscal 2016, the Company accelerated the amortization of its Cystic Fibrosis developed technology asset of $6.2 million as a result of discontinuing this product line. The estimated remaining amortization expense as of July 1, 2017 for each of the five succeeding fiscal years is as follows:
Remainder of Fiscal 2017 | $ | 94.3 |
Fiscal 2018 | $ | 370.4 |
Fiscal 2019 | $ | 358.7 |
Fiscal 2020 | $ | 347.5 |
Fiscal 2021 | $ | 326.0 |

X
- References No definition available. + Details
Name: | us-gaap_GoodwillAndIntangibleAssetsDisclosureAbstract
Namespace Prefix: | us-gaap_
Data Type: | xbrli:stringItemType
Balance Type: | na
Period Type: | duration

X
- Definition The entire disclosure for all or part of the information related to intangible assets. + References Reference 1: http://www.xbrl.org/2003/role/presentationRef -Publisher FASB -Name Accounting Standards Codification -Topic 350 -SubTopic 30 -Section 50 -Paragraph 1 -URI http://asc.fasb.org/extlink&oid=66006027&loc=d3e16265-109275 Reference 2: http://www.xbrl.org/2003/role/presentationRef -Publisher FASB -Name Accounting Standards Codification -Topic 350 -SubTopic 30 -Section 50 -Paragraph 2 -URI http://asc.fasb.org/extlink&oid=66006027&loc=d3e16323-109275 Reference 3: http://www.xbrl.org/2003/role/presentationRef -Publisher FASB -Name Accounting Standards Codification -Topic 350 -SubTopic 30 -Section 50 -Paragraph 3 -URI http://asc.fasb.org/extlink&oid=66006027&loc=d3e16373-109275 + Details
Name: | us-gaap_IntangibleAssetsDisclosureTextBlock
Namespace Prefix: | us-gaap_
Data Type: | nonnum:textBlockItemType
Balance Type: | na
Period Type: | duration